Catalyst Pharmaceuticals, Inc.

NCM: CPRX
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Catalyst Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get CPRX Z-Score →

About Catalyst Pharmaceuticals, Inc.

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

📊 Fundamental Analysis

Catalyst Pharmaceuticals, Inc. demonstrates exceptional profitability, with a profit margin of 36.4%.

The company recently reported 7.6% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is 25.5%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.

At a current price of $24.94, CPRX currently sits at the 78th percentile of its 52-week range (Range: $19.05 - $26.58).

💰 Valuation Insight

CPRX trades at a 40.6% discount (PE: 14.85), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

Profit Margin Excellent
Debt/Equity Excellent
🔴 Revenue Growth Weak
⚠️ Return on Equity Moderate
Beta (Risk) Low Volatility

Key Financials

Market Cap
$3.07B
Trailing P/E
14.85
Forward P/E
8.01
Beta (5Y)
0.66
52W High
$26.58
52W Low
$19.05
Avg Volume
1.21M
Day High
Day Low
Get CPRX Z-Score on Dashboard 🚀